Atara Biotherapeutics, Inc. (NASDAQ:ATRA) has been given a $47.00 price target by Canaccord Genuity in a note issued to investors on Monday. The brokerage currently has a “buy” rating on the biotechnology company’s stock. Canaccord Genuity’s price target would indicate a potential upside of 202.25% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $30.00 target price on shares of Atara Biotherapeutics in a report on Thursday, June 22nd. Zacks Investment Research raised shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 27th. William Blair reaffirmed an “outperform” rating on shares of Atara Biotherapeutics in a report on Monday, June 26th. Finally, ValuEngine lowered shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 1st. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company’s stock. Atara Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $25.75.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.55 on Monday. Atara Biotherapeutics has a 52 week low of $11.80 and a 52 week high of $25.73. The stock has a 50 day moving average of $14.69 and a 200-day moving average of $15.88. The stock’s market capitalization is $452.64 million.

ILLEGAL ACTIVITY WARNING: “Atara Biotherapeutics, Inc. (ATRA) PT Set at $47.00 by Canaccord Genuity” was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/08/07/atara-biotherapeutics-atra-buy-rating-reiterated-at-canaccord-genuity.html.

In related news, CEO Isaac E. Ciechanover sold 6,900 shares of the business’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $13.35, for a total value of $92,115.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares of the company’s stock, valued at approximately $9,770,317.65. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $12.65, for a total transaction of $75,900.00. Following the completion of the sale, the executive vice president now directly owns 368,080 shares of the company’s stock, valued at approximately $4,656,212. The disclosure for this sale can be found here. In the last three months, insiders sold 54,308 shares of company stock valued at $797,382. 16.10% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of the company. American International Group Inc. raised its stake in shares of Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock valued at $294,000 after buying an additional 948 shares during the last quarter. Alps Advisors Inc. raised its stake in shares of Atara Biotherapeutics by 5.8% in the second quarter. Alps Advisors Inc. now owns 26,274 shares of the biotechnology company’s stock valued at $368,000 after buying an additional 1,445 shares during the last quarter. Swiss National Bank raised its stake in shares of Atara Biotherapeutics by 9.6% in the first quarter. Swiss National Bank now owns 28,600 shares of the biotechnology company’s stock valued at $588,000 after buying an additional 2,500 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Atara Biotherapeutics by 11.3% in the second quarter. Rhumbline Advisers now owns 31,373 shares of the biotechnology company’s stock valued at $439,000 after buying an additional 3,175 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Atara Biotherapeutics by 5.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 79,580 shares of the biotechnology company’s stock valued at $1,636,000 after buying an additional 4,446 shares during the last quarter. 81.50% of the stock is owned by institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.